Cristina Ivan

List of Publications by Year in Descending Order

142 papers	8,852 citations	49 h-index	91 g-index
153 ext. papers	10,547 ext. citations	9.5 avg, IF	5.47 L-index

#	Paper	IF	Citations
142	Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.. *Leukemia and Lymphoma*, **2022**, 1-14	1.9	2
141	lncRNAs UC.145 and PRKG1-AS1 Determine the Functional Output of DKK1 in Regulating the Wnt Signaling Pathway in Gastric Cancer. *Cancers*, **2022**, 14, 2369	6.6	
140	Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity. *Journal of the American Chemical Society*, **2021**, 143, 7655-7670	16.4	8
139	Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation. *Science Advances*, **2021**, 7,	14.3	7
138	Explainable Artificial Intelligence Reveals Novel Insight into Tumor Microenvironment Conditions Linked with Better Prognosis in Patients with Breast Cancer. *Cancers*, **2021**, 13,	6.6	2
137	The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. *Oncogene*, **2021**, 40, 384-395	9.2	7
136	PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
135	MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. *Gynecologic Oncology*, **2021**, 163, 181-190	4.9	0
134	Gene Body Methylation of the Lymphocyte-Specific Gene Results in Its Overexpression and Regulates Cancer mTOR Signaling. *Molecular Cancer Research*, **2021**, 19, 1917-1928	6.6	2
133	A novel lncRNA derived from an ultraconserved region: lnc-, a potential biomarker in luminal A breast cancer. *RNA Biology*, **2021**, 1-14	4.8	4
132	Loss of host tissue transglutaminase boosts antitumor T cell immunity by altering STAT1/STAT3 phosphorylation in ovarian cancer **2021**, 9,		1
131	Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. *Molecular Cancer Therapeutics*, **2021**, 20, 2352-2361	6.1	0
130	A New World of Biomarkers and Therapeutics for Female Reproductive System and Breast Cancers: Circular RNAs. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 50	5.7	28
129	Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer. *Gut*, **2020**, 69, 1818-1831	19.2	49
128	miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. *JCI Insight*, **2020**, 5,	9.9	13
127	Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. *Oncotarget*, **2020**, 11, 2819-2833	3.3	2
126	KRCC1: A potential therapeutic target in ovarian cancer. *FASEB Journal*, **2020**, 34, 2287-2300	0.9	4

125	GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. *Cellular Signalling*, **2020**, 68, 109539	4.9	32
124	FuncPEP: A Database of Functional Peptides Encoded by Non-Coding RNAs. *Non-coding RNA*, **2020**, 6,	7.1	10
123	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. *Gastroenterology*, **2020**, 159, 2146-2162.e33	13.3	34
122	Bone morphogenetic protein 7 promotes resistance to immunotherapy. *Nature Communications*, **2020**, 11, 4840	17.4	12
121	Regulation of cellular sterol homeostasis by the oxygen responsive noncoding RNA lincNORS. *Nature Communications*, **2020**, 11, 4755	17.4	7
120	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. *Cancer Immunology Research*, **2020**, 8, 1365-1380	12.5	13
119	Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer. *Journal of the National Cancer Institute*, **2020**, 112, 266-277	9.7	3
118	The non-coding RNome after splenectomy. *Journal of Cellular and Molecular Medicine*, **2019**, 23, 7844-7858	5.6	11
117	MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors. *Breast Cancer Research*, **2019**, 21, 20	8.3	37
116	PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. *EBioMedicine*, **2019**, 40, 290-304	8.8	20
115	Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. *Oncogene*, **2019**, 38, 6095-6108	9.2	29
114	Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. *Cancer Immunology Research*, **2019**, 7, 2036-2051	12.5	24
113	EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. *Oncogene*, **2019**, 38, 2123-2134	9.2	16
112	Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. *Molecular Cancer Therapeutics*, **2019**, 18, 421-436	6.1	7
111	/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. *Molecular Cancer Therapeutics*, **2019**, 18, 162-172	6.1	11
110	Tissue Tranglutaminase Regulates Interactions between Ovarian Cancer Stem Cells and the Tumor Niche. *Cancer Research*, **2018**, 78, 2990-3001	10.1	34
109	A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. *Nature Communications*, **2018**, 9, 461	17.4	39
108	Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA induce myeloid malignancies via unique SNP-specific RNA mutations. *Genome Research*, **2018**, 28, 432-447	9.7	45

107	Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). *Oncogene*, **2018**, 37, 722-731	9.2	23
106	Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. *Journal of Neuro-Oncology*, **2018**, 136, 33-39	4.8	2
105	FABP4 as a key determinant of metastatic potential of ovarian cancer. *Nature Communications*, **2018**, 9, 2923	17.4	82
104	Suppression of PDHX by microRNA-27b deregulates cell metabolism and promotes growth in breast cancer. *Molecular Cancer*, **2018**, 17, 100	42.1	35
103	Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN secretion. *Cancer Letters*, **2018**, 430, 47-56	9.9	57
102	Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion. *Clinical Cancer Research*, **2018**, 24, 4225-4241	12.9	48
101	Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies. *PLoS ONE*, **2018**, 13, e0195932	3.7	5
100	Profiling the circulating miRnome reveals a temporal regulation of the bone injury response. *Theranostics*, **2018**, 8, 3902-3917	12.1	8
99	ADH1B promotes mesothelial clearance and ovarian cancer infiltration. *Oncotarget*, **2018**, 9, 25115-25126	5.3	13
98	Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. *Leukemia*, **2018**, 32, 920-930	10.7	25
97	Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. *Molecular Cancer Therapeutics*, **2018**, 17, 464-473	6.1	3
96	Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. *EBioMedicine*, **2018**, 38, 100-112	8.8	100
95	Circular RNAs: Methodological challenges and perspectives in cardiovascular diseases. *Journal of Cellular and Molecular Medicine*, **2018**, 22, 5176-5187	5.6	45
94	OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. *Scientific Reports*, **2018**, 8, 13106	4.9	12
93	MALAT1 promoted invasiveness of gastric adenocarcinoma. *BMC Cancer*, **2017**, 17, 46	4.8	43
92	Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections. *EBioMedicine*, **2017**, 20, 182-192	8.8	15
91	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. *Clinical Cancer Research*, **2017**, 23, 2891-2904	12.9	90
90	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. *Genome Biology*, **2017**, 18, 98	18.3	75

89	miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5. *Clinical Cancer Research*, **2017**, 23, 5255-5266	12.9	60
88	Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	7
87	TRPA1-FGFR2 binding event is a regulatory oncogenic driver modulated by miRNA-142-3p. *Nature Communications*, **2017**, 8, 947	17.4	26
86	Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. *Oncotarget*, **2017**, 8, 20145-20164	3.3	43
85	MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. *Oncotarget*, **2017**, 8, 11641-11658	3.3	59
84	Regulation of hnRNPA1 by microRNAs controls the miR-18a- axis in chemotherapy-resistant ovarian cancer. *Cell Discovery*, **2017**, 3, 17029	22.3	20
83	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. *Nature Communications*, **2017**, 8, 310	17.4	112
82	Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs. *Nature Communications*, **2017**, 8, 1801	17.4	28
81	Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. *Molecular Therapy - Nucleic Acids*, **2017**, 9, 251-262	10.7	44
80	Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis. *Clinical Cancer Research*, **2017**, 23, 1323-1333	12.9	55
79	Ultraconserved long non-coding RNA uc.63 in breast cancer. *Oncotarget*, **2017**, 8, 35669-35680	3.3	27
78	Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. *JCI Insight*, **2017**, 2,	9.9	20
77	Transcriptome analysis of hypoxic cancer cells uncovers intron retention in EIF2B5 as a mechanism to inhibit translation. *PLoS Biology*, **2017**, 15, e2002623	9.7	23
76	Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells. *Oncotarget*, **2017**, 8, 10905-10918	3.3	10
75	PD-L1 expression and prognostic impact in glioblastoma. *Neuro-Oncology*, **2016**, 18, 195-205	1	331
74	Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. *Oncogene*, **2016**, 35, 2390-7	9.2	51
73	Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. *Oncogene*, **2016**, 35, 2186-96	9.2	24
72	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. *Gut*, **2016**, 65, 977-989	19.2	99

71	Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer. *Neoplasia*, **2016**, 18, 689-698	6.4	24
70	Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. *Cancer Research*, **2016**, 76, 7194-7207	10.1	92
69	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. *Nature Communications*, **2016**, 7, 11169	17.4	83
68	Role of Increased n-acetylaspartate Levels in Cancer. *Journal of the National Cancer Institute*, **2016**, 108, djv426	9.7	32
67	MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. *Neuro-Oncology*, **2016**, 18, 639-481		124
66	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. *Molecular Cell*, **2016**, 61, 520-534	17.6	101
65	Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. *Oncogene*, **2016**, 35, 4312-20	9.2	70
64	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. *Clinical Cancer Research*, **2016**, 22, 1713-24	12.9	47
63	PDL1 Regulation by p53 via miR-34. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	351
62	Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. *JCI Insight*, **2016**, 1, e87754	9.9	10
61	Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. *Oncotarget*, **2016**, 7, 15093-104	3.9	49
60	H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-Catenin Signaling in Colorectal Cancer. *EBioMedicine*, **2016**, 13, 113-124	8.8	84
59	NFAT1 Directly Regulates IL8 and MMP3 to Promote Melanoma Tumor Growth and Metastasis. *Cancer Research*, **2016**, 76, 3145-55	10.1	47
58	Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway. *Oncogene*, **2016**, 35, 4914-26	9.2	41
57	miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	52
56	Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. *Clinical Cancer Research*, **2015**, 21, 2127-37	12.9	49
55	Targeting c-MYC in Platinum-Resistant Ovarian Cancer. *Molecular Cancer Therapeutics*, **2015**, 14, 2260-9	6.1	68
54	The ZNF304-integrin axis protects against anoikis in cancer. *Nature Communications*, **2015**, 6, 7351	17.4	37

53	TP53 loss creates therapeutic vulnerability in colorectal cancer. *Nature*, **2015**, 520, 697-701	50.4	154
52	Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	232
51	PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. *Molecular Cancer Therapeutics*, **2015**, 14, 1466-1475	6.1	11
50	Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis. *Cell Cycle*, **2015**, 14, 2265-73	4.7	22
49	Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. *EBioMedicine*, **2015**, 2, 572-82	8.8	34
48	Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. *Clinical Cancer Research*, **2015**, 21, 448-59	12.9	43
47	Clinically relevant microRNAs in ovarian cancer. *Molecular Cancer Research*, **2015**, 13, 393-401	6.6	75
46	A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. *Molecular Systems Biology*, **2015**, 11, 842	12.2	9
45	Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. *Oncotarget*, **2015**, 6, 29161-77	3.3	75
44	VEGFR-1 Pseudogene Expression and Regulatory Function in Human Colorectal Cancer Cells. *Molecular Cancer Research*, **2015**, 13, 1274-82	6.6	17
43	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. *Cell Reports*, **2015**, 13, 2395-2402	10.6	75
42	Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. *Nature Cell Biology*, **2015**, 17, 311-21	23.4	155
41	Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs. *Oncotarget*, **2015**, 6, 7262-79	3.3	33
40	Low spinophilin expression enhances aggressive biological behavior of breast cancer. *Oncotarget*, **2015**, 6, 11191-202	3.3	9
39	Expression pattern of FGFR2, Grb2 and Plcl acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma. *American Journal of Cancer Research*, **2015**, 5, 3135-48	4.4	9
38	ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. *Blood Cells, Molecules, and Diseases*, **2014**, 53, 47-55	2.1	24
37	Notch3 pathway alterations in ovarian cancer. *Cancer Research*, **2014**, 74, 3282-93	10.1	51
36	Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. *Nature Communications*, **2014**, 5, 5202	17.4	130

35	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. *Nature Communications*, **2014**, 5, 5203	17.4	164
34	Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. *Cancer Cell*, **2014**, 26, 707-21	24.3	1032
33	2ʊOMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. *Nature Communications*, **2014**, 5, 3459	17.4	81
32	Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. *Molecular Cancer Therapeutics*, **2014**, 13, 2583-94	6.1	21
31	Autocrine effects of tumor-derived complement. *Cell Reports*, **2014**, 6, 1085-1095	10.6	118
30	miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. *Molecular Oncology*, **2014**, 8, 83-92	7.9	133
29	HypoxamiRs and cancer: from biology to targeted therapy. *Antioxidants and Redox Signaling*, **2014**, 21, 1220-38	8.4	74
28	Cellular and Kaposiʊ sarcoma-associated herpes virus microRNAs in sepsis and surgical trauma. *Cell Death and Disease*, **2014**, 5, e1559	9.8	30
27	The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression. *Cell Reports*, **2014**, 8, 1447-60	10.6	71
26	MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients. *British Journal of Cancer*, **2014**, 110, 1614-21	8.7	92
25	Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. *Clinical Cancer Research*, **2014**, 20, 3280-8	12.9	55
24	Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner. *Oncotarget*, **2014**, 5, 1185-97	3.3	14
23	Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer. *Oncotarget*, **2014**, 5, 8492-502	3.3	15
22	Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. *Journal of the National Cancer Institute*, **2013**, 105, 1485-95	9.7	121
21	CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. *Genome Research*, **2013**, 23, 1446-61	9.7	442
20	Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. *Cancer Discovery*, **2013**, 3, 1302-15	24.4	123
19	targetHub: a programmable interface for miRNA-gene interactions. *Bioinformatics*, **2013**, 29, 2657-8	7.2	12
18	Tumour angiogenesis regulation by the miR-200 family. *Nature Communications*, **2013**, 4, 2427	17.4	295

17	Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. *Gynecologic Oncology*, **2013**, 128, 506-11	4.9	25
16	Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-□n breast cancer. *Cancer Research*, **2013**, 73, 2884-96	10.1	135
15	Targeting SRC and tubulin in mucinous ovarian carcinoma. *Clinical Cancer Research*, **2013**, 19, 6532-43	12.9	29
14	Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. *Blood*, **2013**, 122, 1891-9	2.2	157
13	CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. *Oncotarget*, **2013**, 4, 1748-62	3.3	148
12	Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. *Frontiers in Oncology*, **2013**, 3, 58	5.3	17
11	ATP11B mediates platinum resistance in ovarian cancer. *Journal of Clinical Investigation*, **2013**, 123, 2119-30	13.9	44
10	ATP11B mediates platinum resistance in ovarian cancer. *Journal of Clinical Investigation*, **2013**, 123, 5411-5411	13.9	78
9	Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells. *Gastroenterology*, **2012**, 142, 886-896.e9	13.3	151
8	p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation. *Cell Cycle*, **2012**, 11, 3433-42	4.7	45
7	Spectral triples and the geometry of fractals. *Journal of Noncommutative Geometry*, **2012**, 249-274	0.4	13
6	Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 4394-9	11.5	183
5	Complex patterns of altered MicroRNA expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer. *Clinical Cancer Research*, **2011**, 17, 7283-93	12.9	57
4	microRNAs in cancer: from bench to bedside. *Advances in Cancer Research*, **2010**, 108, 113-57	5.9	40
3	Extensions and Degenerations of Spectral Triples. *Communications in Mathematical Physics*, **2009**, 285, 925-955	2	3
2	Dirac operators and spectral triples for some fractal sets built on curves. *Advances in Mathematics*, **2008**, 217, 42-78	1.3	37
1	Sums of two-dimensional spectral triples. *Mathematica Scandinavica*, **2007**, 100, 35	0.8	10